ReviewThe Journal of infectious diseases2020
Current Understanding of Cytomegalovirus Reactivation in Critical Illness.
Review in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Does treatment with antiviral medication affect mortality among immunocompetent individuals with cytomegalovirus reactivation? A systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Association Between Cytomegalovirus Infection and Tuberculosis Disease: A Systematic Review and Meta-Analysis of Epidemiological Studies.The Journal of infectious diseases · 2023Pooled it
- Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Pooled it
- CMV and HHV-6 reactivation in immunocompetent patients hospitalised in the ICU - is it a real problem? A case series and narrative review.Anaesthesiology intensive therapy · 2026Review
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on "Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation".Clinical and molecular hepatology · 2026Article
- Cytomegalovirus-Associated Parainfectious Miller Fisher Syndrome Without Anti-GQ1b Antibodies: A Case Report.The Neurohospitalist · 2026Article
- Infections after bispecific antibodies in B-cell lymphomas.Blood advances · 2026Article
- Time-series clustering analysis reveals distinct patterns of cytomegalovirus viremia in critically ill adults.Intensive care medicine experimental · 2026Article
- Pathogen landscape and synergistic interactions in pediatric ARIs: implications for broad-spectrum surveillance via targeted NGS.Microbiology spectrum · 2026Article
- Clinical and biological features of CMV reactivation in ARDS: a prospective cohort study.Critical care (London, England) · 2026Article
- Reactivation ofCase reports in infectious diseases · 2026Article
- Associated Factors on Cytomegalovirus Reactivation in Patients with COVID-19 in the Intensive Care Unit.Mediterranean journal of hematology and infectious diseases · 2026Article
- The Dynamics of Human Cytomegalovirus Markers in Tuberculosis Disease Among People With Human Immunodeficiency Virus on Long-term Antiretroviral Therapy: A Nested Case-Control Study.Open forum infectious diseases · 2026Article
- Risk stratification for CMV reactivation in sepsis patients: development of an interpretable machine learning model.BMC infectious diseases · 2025Article
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Risk factors associated with cytomegalovirus reactivation and disease in critically-ill COVID-19 and non-COVID-19 patients, concomitantly admitted to intensive care.Scientific reports · 2025Article
- The indirect effects of cytomegalovirus infection-mechanisms and consequences.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Observational
- Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation.Clinical and molecular hepatology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cytomegalovirus (CMV) reactivation has been described in adults with critical illness caused by diverse etiologies, especially severe sepsis, and observational studies have linked CMV reactivation with worse clinical outcomes in this setting. In this study, we review observational clinical data linking development of CMV reactivation with worse outcomes in patients in the intensive care unit, discuss potential biologically plausible mechanisms for a causal association, and summarize results of initial interventional trials that examined the effects of CMV prevention. These data, taken together, highlight the need for a randomized, placebo-controlled efficacy trial (1) to definitively determine whether prevention of CMV reactivation improves clinical outcomes of patients with critical illness and (2) to define the underlying mechanism(s).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.